and recommendation
Stemline Therapeutics, Inc. (STML)
Stemline Therapeutics (STML) a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics.
STML develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.
STML also develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development.
Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
- June 10, 2013 - 7:46am | Research Notes, Regulatory
- May 23, 2013 - 8:31am | Financings
- May 22, 2013 - 8:16pm | Out and About
- May 22, 2013 - 4:05pm | Financings
- May 7, 2013 - 8:32am | Financings
- February 1, 2013 - 8:36am | Financings
Pages
- « first
- ‹ previous
- 1
- 2
- 3
- 4